loading
前日終値:
$2.85
開ける:
$2.79
24時間の取引高:
40,434
Relative Volume:
0.11
時価総額:
$248.18M
収益:
$351.37M
当期純損益:
$-174.01M
株価収益率:
-1.401
EPS:
-2.07
ネットキャッシュフロー:
$-126.94M
1週間 パフォーマンス:
+5.66%
1か月 パフォーマンス:
+1.58%
6か月 パフォーマンス:
-14.09%
1年 パフォーマンス:
-21.54%
1日の値動き範囲:
Value
$2.79
$2.905
1週間の範囲:
Value
$2.71
$2.965
52週間の値動き範囲:
Value
$2.455
$4.145

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name
名前
Atea Pharmaceuticals Inc
Name
セクター
Healthcare (1178)
Name
電話
857-204-8109
Name
住所
225 FRANKLIN STREET, BOSTON
Name
職員
56
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
AVIR's Discussions on Twitter

AVIR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
AVIR
Atea Pharmaceuticals Inc
2.90 221.65M 351.37M -174.01M -126.94M -2.07
Biotechnology icon
ONC
Beigene Ltd Adr
241.57 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
431.80 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.33 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
586.69 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.12 5.92B 0 -153.72M -103.81M -2.00

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-08-13 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-08-10 ダウングレード JP Morgan Neutral → Underweight
2022-01-06 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-11-18 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-10-20 ダウングレード JP Morgan Overweight → Neutral
2021-10-05 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-11-25 開始されました Evercore ISI Outperform
2020-11-24 開始されました JP Morgan Overweight
2020-11-24 開始されました Morgan Stanley Overweight
2020-11-24 開始されました William Blair Outperform
すべてを表示

Atea Pharmaceuticals Inc (AVIR) 最新ニュース

pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 17, 2025
pulisher
May 16, 2025

Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World

May 16, 2025
pulisher
May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025
pulisher
May 14, 2025

Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 14, 2025
pulisher
May 14, 2025

Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks

May 14, 2025
pulisher
May 12, 2025

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025
pulisher
May 10, 2025

Wells Fargo & Company MN Increases Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 10, 2025
pulisher
May 10, 2025

Atea Pharmaceuticals (AVIR) to Release Earnings on Monday - Defense World

May 10, 2025
pulisher
May 08, 2025

Atea reports high efficacy in Phase 2 HCV drug trial By Investing.com - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Increases Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 08, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals (AVIR) Reveals Promising Phase 2 Results for Hepatitis C Treatment | AVIR Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Atea reports high efficacy in Phase 2 HCV drug trial - Investing.com

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results from Phase 2 - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - Stock Titan

May 07, 2025
pulisher
May 01, 2025

A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals (AVIR) Organizes HCV Treatment Panel & Announces Q1 Results | AVIR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times

May 01, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX

Apr 25, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News

Apr 22, 2025
pulisher
Apr 18, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharma Doubles Down: $25M Share Buyback Plan Unveiled as Strategic Review Accelerates - Stock Titan

Apr 17, 2025
pulisher
Apr 13, 2025

Morgan Stanley Issues Pessimistic Forecast for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price - Defense World

Apr 13, 2025
pulisher
Apr 11, 2025

Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR - Benzinga

Apr 11, 2025
pulisher
Apr 10, 2025

Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study - MSN

Apr 10, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan

Apr 09, 2025
pulisher
Apr 05, 2025

HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 05, 2025
pulisher
Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com

Apr 01, 2025

Atea Pharmaceuticals Inc (AVIR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.19
price down icon 13.67%
$31.50
price down icon 3.35%
$578.71
price down icon 0.54%
$285.49
price down icon 1.39%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
大文字化:     |  ボリューム (24 時間):